Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The maximum days the report can be obtained for the test PD-L1 Clone SP263 Test Immunohistochemistry is 14 days.

What are the prerequisites for the test PD-L1 Clone SP263 Test Immunohistochemistry

  • Tissue samples fixed in 10% neutral buffered formalin for 6 to 72 hours.
  • Paraffin-embedded tissue blocks.
  • 4-micron thick tissue sections mounted on positively charged slides.
  • Positive and negative controls for the assay.
  • Appropriate reagents and equipment for immunohistochemistry.

What are the measure values for the test PD-L1 Clone SP263 Test Immunohistochemistry

Measure Value
Positive Tumor Cell (PTC) Percentage >1%
TC Score >1
Immune Cell (IC) Percentage >1%
IC Score >1

What does this test PD-L1 Clone SP263 Test Immunohistochemistry identify?

  • This test identifies the Programmed Death Ligand 1 (PD-L1) protein expression in tissue samples.
  • It uses the SP263 clone antibody to detect PD-L1, which is a protein that plays a role in regulating the immune response.
  • PD-L1 expression in tumor cells is important for predicting response to immunotherapy in certain cancers.
  • Results of this test can help guide treatment decisions and prognosis for patients with cancer.

Why is this test PD-L1 Clone SP263 Test Immunohistochemistry taken?

The PD-L1 Clone SP263 Test Immunohistochemistry is taken to detect the expression of Programmed Death-Ligand 1 (PD-L1) in tissue samples. PD-L1 is a protein that plays a crucial role in regulating the immune response by binding to its receptor PD-1 on T cells, thereby inhibiting their activity. High levels of PD-L1 expression in tumor cells have been associated with immune evasion and resistance to immunotherapy.

By performing the PD-L1 Clone SP263 Test Immunohistochemistry, healthcare providers can determine the level of PD-L1 expression in tumor cells, which can help guide treatment decisions for patients with certain types of cancer. This test is commonly used in the management of various cancers, such as non-small cell lung cancer and urothelial carcinoma, to identify patients who may benefit from therapies targeting the PD-1/PD-L1 pathway.

No FAQs available.

Customer Google Rating